Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Skye Bioscience Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SKYE
Nasdaq
8731
https://skyebioscience.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Skye Bioscience Inc
Skye Bioscience to Present at Upcoming Investment Conferences
- Apr 23rd, 2024 11:00 am
Skye Bioscience Uplists to The Nasdaq Global Market
- Apr 10th, 2024 12:00 pm
Skye Bioscience Announces $40 Million Private Placement Equity Financing
- Mar 11th, 2024 1:20 pm
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
- Mar 4th, 2024 12:00 pm
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
- Feb 26th, 2024 12:00 pm
Skye Bioscience to Present at Oppenheimer Investor Conference
- Feb 7th, 2024 12:00 pm
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
- Jan 29th, 2024 1:00 pm
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
- Jan 9th, 2024 12:00 pm
Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab
- Dec 11th, 2023 12:00 pm
Skye Bioscience Responds to OTC Markets Promotional Policy
- Dec 8th, 2023 10:14 pm
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
- Dec 5th, 2023 12:00 pm
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
- Nov 28th, 2023 12:00 pm
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
- Nov 21st, 2023 12:00 pm
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
- Oct 25th, 2023 11:00 am
CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"
- Oct 20th, 2023 4:59 am
Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"
- Oct 19th, 2023 11:00 am
Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
- Sep 27th, 2023 11:00 am
Skye Bioscience Announces Participation at Upcoming Investor Conferences
- Sep 22nd, 2023 11:00 am
Skye Bioscience Reverse Stock Split to Be Effective on September 8th
- Sep 7th, 2023 5:00 pm
Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 11:00 am
Scroll